A Case of Xenon Inhalation Therapy for Respiratory Failure and Neuropsychiatric Disorders Associated With COVID-19 | Sciact - CRIS-система Института катализа

A Case of Xenon Inhalation Therapy for Respiratory Failure and Neuropsychiatric Disorders Associated With COVID-19 Научная публикация

Журнал

EXCLI Journal
ISSN: 1611-2156

Вых. Данные

Год: 2021, Номер: 20, Страницы: 1517-1525 Страниц : 9 DOI: 10.17179/excli2021-4316

Ключевые слова

SARS-CoV-2, xеnon, surfactant, respiratory failure, neuropsychiatric disorders, molecular modeling

Авторы

Udut Vladimir Vasil’evich ¹ , Naumov Sergei Alexandrovich ¹ , Evtushenko Diana Nikolaevna ² , Udut Elena Vladimirovna ^1,3 , Naumov Sergei Sergeevich ³ , Zyuz’kov Gleb Nikolaevich ¹

Организации

1	Tomsk National Research Medical Center, Russian Academy of Sciences, Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk, Russia
2	Tomsk State University, Tomsk, Russia
3	Siberian State Medical University, Tomsk, Russia

Acute respiratory distress syndrome (ARDS) is the main danger to the life of patients with pneumonia caused by SARS-CoV-2. At the same time, respiratory failure (RF) after ARDS can persist for a long time despite intensive therapy. Therefore, it is important to develop new effective approaches for restoring the ventilation function of the lungs after COVID-19. Here, we present a case report of effective application of short-term inhalations of xenon-oxygen (Xe/O2) gas mixture for treatment of RF and neuropsychiatric disorders (NPD) associated with COVID-19. The patient inhaled a gas mixture of 70 % Xe and 30 % O2. We used multispiral computed tomog-raphy, evaluated psychometry, studied hematological and biochemical blood parameters, and applied some other methods of clinical studies to assess the therapeutic effectiveness of Xe inhalation. Also, we studied the mecha-nism of action of xenon with computer modeling. The clinical case showed the high efficacy of Xe/O2 mixture for treating severe RF and NPD after SARS-CoV-2 infection. Xenon inhalations dramatically increased oxygen saturation and the degree of pneumatization of the lungs. We found out that in coronavirus pneumonia, saturated phospholipids of surfactant are transferred to the solid-ordered phase, which disrupts the surface tension of the alveoli and alveolar gas exchange. Using molecular modeling methods, we demonstrated that the xenon atom in-creases the distance between the acyl chains of phospholipids due to the van der Waals dispersion interaction. These changes allow for the phase transition of phospholipids from the solid-ordered phase to the liquid phase and restore the functional activity of the surfactant. The findings suggest the feasibility of conducting studies on the effectiveness of Xe/O2 inhalations for treating ARDS in SARS-CoV-2 infection.

Udut V.V. , Naumov S.A. , Evtushenko D.N. , Udut E.V. , Naumov S.S. , Zyuz’kov G.N.
A Case of Xenon Inhalation Therapy for Respiratory Failure and Neuropsychiatric Disorders Associated With COVID-19
EXCLI Journal. 2021. N20. P.1517-1525. DOI: 10.17179/excli2021-4316 WOS Scopus PMID OpenAlex

Поступила в редакцию:	16 сент. 2021 г.
Принята к публикации:	25 окт. 2021 г.
Опубликована в печати:	28 окт. 2021 г.
Опубликована online:	28 окт. 2021 г.

Web of science:	WOS:000712684300001
Scopus:	2-s2.0-85118500121
PMID (PubMed):	34924901
OpenAlex:	W3212684908

БД	Цитирований
OpenAlex	6
Web of science	6
Scopus	7